An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital

Baruch, Nina; Das, M.B.; Sharda, Amit; Basu, Amlan; Bajorek, Thomas; Ross, Callum; Sengupta, Samrat; Larkin, Fintan; Young, Susan

doi:10.1177/2045125314531982

Cited by 22 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding supports the available efficacy data of olanzapine LAI in patients with schizophrenia [27,28] and occasional case reports which have reported a beneficial effect of olanzapine LAI in patients with TRS. [35,36] Present study results also show that the majority of the patients continued to receive olanzapine LAI with a mean duration of 17 months. Only about one-fourth of the patients discontinued olanzapine LAI, of whom half were reluctant to receive the injection.…”

Section: Discussionsupporting

confidence: 62%

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital

Grover¹,

Singla²,

Chakrabarti³

2020

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Background: Little is known from India about the experience of using olanzapine long-acting antipsychotic injectables (LAI). In this background, this study aimed to evaluate the clinical profile of patients suffering from schizophrenia who were prescribed olanzapine LAI and to evaluate the usefulness and acceptability of olanzapine LAI among these patients. Methods: In this retrospective study, data of all the patients with schizophrenia receiving olanzapine pamoate, was extracted. Results: 40 patients (males-55%; mean [SD] age-36.2 (12) years; mean duration of illness (SD) prior to depot-143.3 (115.9) months) were included in the study. Olanzapine LAI was invariably prescribed in patients with a past history of non-compliance. Data was available for a mean (SD) follow-up duration of 17 (10.8) months. The most frequently used dose of olanzapine LAI used was 300 mg every two weeks (55%). This was followed by 405 mg every four weeks in (32.5%). Mean Clinical Global Impression (CGI) Severity score prior to starting of olanzapine LAI was 5.8 (0.7), which reduced to 2.7 (1.1) at the time of last follow-up or the last use of olanzapine LAI, and this was a statistically significant improvement (paired t-test value = 16.41; P < 0.001). Only one (2.5%) patient experienced Post injection Delirium/Sedation Syndrome during the study period. Only one patient was hospitalized after starting depot olanzapine. Conclusion: Olanzapine LAI is mostly used in patients with a history of non-compliance. Olanzapine LAI is associated with a significant reduction in the severity of illness.

show abstract

Section: Discussionsupporting

confidence: 62%

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital

Grover¹,

Singla²,

Chakrabarti³

2020

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

show abstract

“…19,20 There are previous studies from HSHs reporting the benefit of the use of LAI antipsychotic medication. 21,22 Although it has not been explored in the literature, it can be hypothesized that LAI antipsychotics may be beneficial to violent schizophrenia patients such as ours because of the reduction in noncompliance it offers.…”

Section: Antipsychotic Polypharmacy and High-dose Prescribingmentioning

confidence: 99%

Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital

et al. 2016

Self Cite

View full text Add to dashboard Cite

Rates of clozapine and high-dose antipsychotic prescribing were higher than in other psychiatric settings, while polypharmacy prescribing rates were lower. Higher clozapine prescribing rates may be a function of a treatment-resistant and aggressive population. A higher proportion of PD-only patients consented to treatment and received clozapine compared with in-house SSD-only as well as other psychiatric settings. Implications of the findings are discussed.

show abstract

“…Several studies have shown that LAI-APs may reduce the risk of relapse and hospitalisation. There is also some preliminary evidence that LAIs may reduce comorbid violent behaviour in patients with schizophrenia [6,7].…”

Section: Effectiveness Of Sgr Laismentioning

confidence: 99%

Reducing the stigma of long acting injectable antipsychotics – current concepts and future developments

Taylor

Velaga

Werneke

2018

Nordic Journal of Psychiatry

View full text Add to dashboard Cite

show abstract

An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital

Cited by 22 publications

References 17 publications

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital

Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital

Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital

Reducing the stigma of long acting injectable antipsychotics – current concepts and future developments

Contact Info

Product

Resources

About